S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
Log in
NASDAQ:VVOS

Vivos Therapeutics Stock Forecast, Price & News

$7.07
+0.35 (+5.21 %)
(As of 01/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.75
Now: $7.07
$7.14
50-Day Range N/A
52-Week Range
$5.64
Now: $7.07
$14.41
Volume216,204 shs
Average Volume254,101 shs
Market Capitalization$124.91 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
There is no company description available for Vivos Therapeutics Inc.

MarketRank

Overall MarketRank

1.69 out of 5 stars

-- Sector

1st out of 134 stocks

-- Industry

1st out of 135 stocks

Analyst Opinion: 3.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry --
Sub-IndustryN/A
Sector--
Current SymbolNASDAQ:VVOS
CUSIPN/A
CIKN/A
WebN/A
PhoneN/A
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$124.91 million
Next Earnings DateN/A
OptionableNot Optionable
$7.07
+0.35 (+5.21 %)
(As of 01/21/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VVOS News and Ratings via Email

Sign-up to receive the latest news and ratings for VVOS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Vivos Therapeutics (NASDAQ:VVOS) Frequently Asked Questions

Is Vivos Therapeutics a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vivos Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Vivos Therapeutics stock.
View analyst ratings for Vivos Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Vivos Therapeutics?

Wall Street analysts have given Vivos Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Vivos Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Vivos Therapeutics' CEO?

1,448 employees have rated Vivos Therapeutics CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Vivos Therapeutics' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What price target have analysts set for VVOS?

2 brokerages have issued 1-year target prices for Vivos Therapeutics' stock. Their forecasts range from $12.00 to $12.00. On average, they expect Vivos Therapeutics' stock price to reach $12.00 in the next year. This suggests a possible upside of 69.7% from the stock's current price.
View analysts' price targets for Vivos Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of Vivos Therapeutics' key competitors?

When did Vivos Therapeutics IPO?

(VVOS) raised $20 million in an IPO on Friday, December 11th 2020. The company issued 3,300,000 shares at $5.00-$7.00 per share. Roth Capital Partners acted as the underwriter for the IPO and Craig-Hallum Capital Group and National Securities Corporation were co-managers.

What is Vivos Therapeutics' stock symbol?

Vivos Therapeutics trades on the NASDAQ under the ticker symbol "VVOS."

When did Vivos Therapeutics' quiet period expire?

Vivos Therapeutics' quiet period expired on Wednesday, January 20th. Vivos Therapeutics had issued 3,500,000 shares in its initial public offering on December 11th. The total size of the offering was $21,000,000 based on an initial share price of $6.00. During Vivos Therapeutics' quiet period, underwriters and any insiders that worked on the IPO were prevented from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Vivos Therapeutics?

Shares of VVOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Vivos Therapeutics' stock price today?

One share of VVOS stock can currently be purchased for approximately $7.07.

How big of a company is Vivos Therapeutics?

Vivos Therapeutics has a market capitalization of $124.91 million.

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.